I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

I've done extensive searches for a dividend stock that investors can actually sleep well owning, and I keep coming back to Johnson & Johnson (NYSE: JNJ). Right now, it doesn't have the flashiest yield, but the way it treats its dividend and the kind of business behind that payout make it, in my view, the best dividend stock to buy.

Johnson & Johnson has raised its dividend annually for 64 consecutive years, a streak that covers multiple recessions, rate cycles, patent cliffs, and restructurings. This increase makes it a Dividend King. In April 2026, the board lifted the quarterly per-share dividend from $1.30 to $1.34, a 3.1% increase, and reaffirmed the payout again in July for the third quarter. The annual dividend now sits around $5.36 per share, with a yield near 2% at current prices, and total shareholder yield looks higher once you factor in buybacks. That combination isn't meant to shock you. It's meant to quietly compound.

Image source: Getty Images.

What should give confidence is the business behind those checks. Johnson & Johnson is now a focused healthcare company with two engines: Innovative Medicine and MedTech. The pharma side works in oncology, immunology, neuroscience, and cardiopulmonary diseases, selling branded medicines through hospitals and doctors who treat cancer, autoimmune conditions, and mood disorders. The MedTech side builds devices and surgical tools used in cardiovascular care, orthopedics, operating rooms, and vision care, from heart recovery systems and electrophysiology gear to robotic surgery platforms and contact lenses.

Diversification is key

That breadth matters for a dividend investor. J&J does not rely on one blockbuster drug or one device category to fund its payout. It has 28 drug or product platforms generating at least $1 billion of annual revenue, which spreads risk across many therapies and technologies. In the most recent quarter, total sales grew nearly 7% to about $25.31 billion, led by strong performance in oncology and immunology medicines such as Darzalex and Tremfya, while MedTech still delivered growth despite missing analyst expectations. The company even raised its full-year 2026 sales and earnings guidance, now targeting around $101.1 billion of revenue and higher adjusted EPS than previously planned.

This is also a company that treats future relevance as seriously as current cash. Johnson & Johnson MedTech is in the midst of a strategic pivot, shedding its DePuy Synthes orthopedics business and concentrating on higher-growth, higher-margin areas such as cardiovascular, surgery, and vision. It has integrated acquisitions like Abiomed and Shockwave Medical and filed for FDA approval of its Ottava robotic surgical system, which is designed to bring more integrated, table-based robotics into operating rooms. On the pharma side, J&J continues to invest in oncology and neuroscience pipelines and has laid out plans to bring at least 20 novel therapies or major product expansions to market by 2030.

Johnson & Johnson is a solid, staple investment for right now

This is not a company resting on its past accomplishments. In 2026, Johnson & Johnson was again named a Fortune World's Most Admired Company for the 24th year in a row and ranked as the top healthcare company on The Wall Street Journal's Best Companies for the Future list. Those rankings reflect how peers and investors view J&J's ability to evolve. Also, right now, it seems like a lot of money is moving in and out of AI and tech trades. This company has a solid dividend and is a safe, reliable, growing cash payout machine backed by a diversified healthcare business. It's safe for the current volatile market.

From a dividend perspective, that kind of stability and reinvention is exactly what dividend investors want. A payout that has grown for six decades tells me management sees the dividend as a promise, not a lever to pull only when times are good. A diversified, innovative business spanning medicine and MedTech shows that the cash to honor that promise will keep coming in.

Investors looking for a great long-term dividend-paying investment would do well to take a closer look at Johnson & Johnson.

Micah Zimmerman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.